Trial Profile
ESCALATE-RA A NON-INTERVENTIONAL STUDY OF CRITICAL FACTORS FOR ESCALATING DRUG TREATMENT IN PATIENTS TREATED WITH TOFACITINIB FOR MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs Tofacitinib (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms ESCALATE-RA
- Sponsors Pfizer
- 07 Sep 2023 Status changed from recruiting to completed.
- 14 Nov 2022 Interim results (data cut off-31 Jan 2022, n= 704) presented at the ACR Convergence 2022
- 23 Apr 2021 Planned End Date changed from 1 Nov 2022 to 23 Jul 2023.